Open AccessPopulation Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
Author(s) -
Pavan Vaddady,
Bhargava Kandala,
Ka Lai Yee
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00590-20
Subject(s) - lamivudine , reverse transcriptase inhibitor , pharmacokinetics , pharmacology , population , regimen , nucleoside reverse transcriptase inhibitor , pharmacodynamics , medicine , nucleoside , tenofovir , human immunodeficiency virus (hiv) , virology , sida , chemistry , virus , antiretroviral therapy , viral disease , viral load , stereochemistry , hepatitis b virus , environmental health
Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-SHIFT trial and used to estimate individual post hoc PK parameter values and evaluate the efficacy exposure-response relationship. The results support the 100-mg dose for people living with HIV switching to a doravirine-based regimen (This study has been registered at ClinicalTrials.gov under ClinicalTrials registration no. NCT02397096.).